Share Buyback & Completion of Share Buyback Prog.

About this update from Ekf Diagnostics Holdings Plc

EKF Diagnostics Holdings plc ("EKF" or the "Company")   Share Buyback & Completion of Share Buyback Programme   EKF Diagnostics Holdings plc  (AIM: EKF), the AIM-listed global diagnostics business, announces that it has purchased a total of 367,000 of its ordinary shares of 1p each in the capital of the Company (" Ordinary Shares ") at a weighted average price of 21.5 pence per share. The Ordinary Shares purchased will be held in treasury.   This transaction marks the successful conclusion of the share buyback programme as set out in the announcement on 1 April 2025. Pursuant to the share buyback programme, a total of 4,636,774 ordinary shares were purchased at a weighted average cost of 21.48 pence per Ordinary Share.   Aggregated information   Date of purchase 12 May 2025 Number of Ordinary Shares purchased 367,000 Highest price paid per Ordinary Share 21.5p Lowest price paid per Ordinary Share 21.5p Volume weighted average price paid 21.5p     Transaction details   In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018), a detailed breakdown of individual trades is available below:   Number of Ordinary Shares purchased Transaction price (GBp) Time of transaction Trading venue 258,775 21.5p 09:39:55 AIMX 108,225 21.5p 09:55:18 AIMX   Total voting rights   Following the purchase, the Company's total issued share capital will consist of 454,930,564 Ordinary Shares each carrying one voting right, of which 5,836,774 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 449,093,790. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.   PDMR dealing   As part of the buyback and within the above aggregate purchase, EKF acquired 108,225 Ordinary Shares in total at a price of 21.5 pence per Ordinary Share from Harwood as investment manager to Oryx International Growth Fund Limited (" Oryx ") and North Atlantic Smaller Companies Investment Trust PLC (" NASCIT "). EKF acquired 36,075 and 72,150 Ordinary Shares from Oryx and NASCIT respectively. Harwood has facilitated this transaction solely in order to ensure that the aggregate indirect beneficial interest of Mr. Mills remains at approximately the same level and in any event does not exceed 30% of the prevailing total voting rights in the Company following any repurchases.   Following the above sale of Ordinary Shares by Oryx and NASCIT to the Company, Mr. Mills' aggregate indirect interest in the Company is 132,433,193 Ordinary Shares.    Additional disclosures relating to this PDMR dealing are detailed below.   This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).      The person responsible for arranging the release of this Announcement on behalf of the Company is Julian Baines, Executive Chair.     EKF Diagnostics Holdings plc www.ekfdiagnostics.com Julian Baines, Executive Chair  via Walbrook PR Gavin Jones, Chief Executive Officer   Singer Capital Markets (Nominated Adviser & Broker) Tel: +44 (0)20 7496 3000 Phil Davies / Oliver Platts Walbrook PR Limited Tel: +44 (0)20 7933 8780 or [email protected] Paul McManus / Alice Woodings  Mob: +44 (0)7980 541 893 / +44 (0) 7407 804 654       About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )   EKF is an AIM-listed global diagnostics business focussed on:   ● Point-of-Care  analysers in the key areas of Hematology and Diabetes  ● Life Sciences  services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.   EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.   Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them   1   Details of the person discharging managerial responsibilities / person closely associated   a)   Name Christopher Mills 2   Reason for the notification   a)   Position/status   Non-Executive Director b)   Initial notification /Amendment   Initial Notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name EKF Diagnostics Holdings plc b)   LEI   213800DXTF3EAUK1AR05   4   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted   a)   Description of the financial instrument, type of instrument Ordinary Shares of 1 pence each Identification code GB0031509804   b)   Nature of the transaction     Disposal of Ordinary Shares c)   Price(s) and volume(s) Price(s) Volume(s) 21.5p 108,225 d)   Aggregated information - Aggregated volume n/a - Price e)   Date of the transaction       12 May 2025 f)   Place of the transaction     London Stock Exchange, AIMX      

View stock analysis, news, and events for Ekf Diagnostics Holdings Plc